<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02104648</url>
  </required_header>
  <id_info>
    <org_study_id>BP29269</org_study_id>
    <nct_id>NCT02104648</nct_id>
  </id_info>
  <brief_title>A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval</brief_title>
  <official_title>A 2 PART STUDY IN HEALTHY SUBJECTS: PART A: A MULTIPLE DOSE, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SUPRA-THERAPEUTIC DOSES OF RO4602522; PART B: A MULTIPLE-DOSE, RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PLACEBO CONTROLLED, POSITIVE-CONTROL, PARALLEL GROUP STUDY TO INVESTIGATE THE EFFECT OF RO4602522 ON THE QTC INTERVAL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This is a 2 part study to evaluate the safety and tolerability of supra-therapeutic doses of
      RO4602522 (Part A); and to investigate the effect of RO4602522 on the QTcF interval in
      healthy volunteers (Part B). Part A of the study will be a multiple-dose, randomized,
      double-blind, placebo-controlled study. Participants will be randomized to receive daily,
      oral doses of either RO4602522 or placebo for ten days. Part B of the study will be a
      multiple-dose, randomized, double-blind, double-dummy, placebo controlled, positive-control,
      parallel group study. Participants will be randomized to receive either multiple or single
      doses of RO4602522 or to receive single doses of moxifloxacin for 11 days. Pharmacokinetic
      parameters will be assessed for Parts A and B; and continuous ECG recordings will be made
      during Part B.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Incidence of adverse events</measure>
    <time_frame>Up to 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Continuous, 12-lead, Holter electrocardiogram (ECG) recordings</measure>
    <time_frame>Days -1 (screening) to 11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parts A &amp; B: Area under the concentration-time curve (AUC) of RO4602522</measure>
    <time_frame>Days 1 to 10</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">203</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: RO4602522</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: RO4602522 Multiple Doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: RO4602522 Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: moxifloxacin Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo RO4602522</intervention_name>
    <description>Daily oral doses</description>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_label>Part B: RO4602522 Single Dose</arm_group_label>
    <arm_group_label>Part B: moxifloxacin Single Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO4602522</intervention_name>
    <description>Daily oral doses</description>
    <arm_group_label>Part A: RO4602522</arm_group_label>
    <arm_group_label>Part B: RO4602522 Multiple Doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO4602522</intervention_name>
    <description>Single, oral dose</description>
    <arm_group_label>Part B: RO4602522 Single Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin</intervention_name>
    <description>400 mg oral dose given on Day 1 or 11</description>
    <arm_group_label>Part B: moxifloxacin Single Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>moxifloxacin placebo</intervention_name>
    <description>Dose given orally on Days 1 and/or 11</description>
    <arm_group_label>Part B: RO4602522 Multiple Doses</arm_group_label>
    <arm_group_label>Part B: RO4602522 Single Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects, 18 to 65 years of age, inclusive. For Part B:
             Healthy male and female subjects, 18 to 65 years of age, inclusive (female subjects
             only if the repeat dose is tolerated in Part A)

          -  Healthy status is defined by absence of evidence of any clinically significant, active
             or chronic disease following a detailed medical and surgical history, a complete
             physical examination including vital signs, 12-lead ECG, hematology, blood chemistry,
             serology and urinalysis

          -  A BMI between 18 to 32 kg/m2 inclusive

          -  Use of highly effective contraception

        Exclusion Criteria:

          -  Pregnant or breast-feeding women

          -  Suspicion of alcohol or drug abuse or positive drug screen

          -  Positive result on hepatitis B (HBsAg), hepatitis C (HCV), or HIV 1 and 2

          -  History of any clinically significant gastrointestinal, renal, hepatic,
             broncho-pulmonary, neurological, psychiatric, cardio-vascular, endocrinological,
             hematological or allergic disease, metabolic disorder, cancer or cirrhosis

          -  Diseases or medical conditions that are capable of altering the absorption, metabolism
             or elimination of drugs

          -  Any prescribed or over-the-counter medications (including vitamins or herbal remedies)
             taken within 2 weeks prior to first dosing or within 5 times the elimination half-life
             of the medication prior to first dosing (whichever is longer)

          -  Taking any nutrients known to modulate CYP3A activity (e.g., grapefruit juice; Seville
             orange) within 2 weeks prior to administration of study drugs or tyramine rich
             nutrients 48 hours prior to admission to study site and then throughout the study

          -  Participation in an investigational drug or device study within 60 days prior to
             screening or 5 times the elimination half-life of the medication prior to first dosing
             (whichever is longer)

          -  Consumption of nicotine and/ or tobacco products within the last 45 days prior to Day
             1 of study

        Part B

          -  Any clinically significant cardiovascular findings or history of such

          -  Allergy to moxifloxacin or any quinolone antibiotics or history of tendon rupture with
             quinolone-type antibiotic or any confirmed clinically significant allergic reactions
             against any drug, or multiple allergies in the judgment of the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2014</study_first_submitted>
  <study_first_submitted_qc>April 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2014</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

